GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Net Change in Cash

BMY (Bristol-Myers Squibb Co) Net Change in Cash : $325 Mil (TTM As of Sep. 2024)


View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Bristol-Myers Squibb Co's Net Change in Cash for the three months ended in Sep. 2024 was $1,597 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $325 Mil.

Bristol-Myers Squibb Co Net Change in Cash Historical Data

The historical data trend for Bristol-Myers Squibb Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Net Change in Cash Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,909.00 2,153.00 -657.00 -4,991.00 2,194.00

Bristol-Myers Squibb Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -857.00 3,951.00 -2,185.00 -3,038.00 1,597.00

Bristol-Myers Squibb Co Net Change in Cash Calculation

Bristol-Myers Squibb Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=13860+-2295+-9416+45
=2,194

Bristol-Myers Squibb Co's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=5591+-219+-3852+77
=1,597

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $325 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Net Change in Cash
Comparable Companies
GILD PFE AMGN BIIB OGN AMRN SCLX MIRA MRK ABBV LLY OCSE:NOVO B JNJ XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 TSE:4568
Traded in Other Exchanges
BMYMP.PFD:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina
Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Website
https://www.bms.com
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Executives
Samit Hirawat officer: Chief Medical Offr., Drug Dev. BRISTOL-MYERS SQIUBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543

Bristol-Myers Squibb Co Headlines

From GuruFocus

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

By Business Wire • 11-05-2024

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY� (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

By Business Wire • 09-28-2024

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS� (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

By Business Wire • 09-01-2024

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024

By Business Wire • 10-28-2024

Bristol-Myers Squibb Co (BMY) Trading Down 3.9% on Nov 16

By GuruFocus News • 11-16-2024

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY� (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

By Business Wire • 09-27-2024

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

By Business Wire • 09-18-2024

Bristol-Myers Squibb Co (BMY) Stock Price Up 12.09% on Nov 11

By GuruFocus News • 11-11-2024

Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Investments Propel Future Prospects

By GuruFocus News • 11-01-2024

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

By Business Wire • 09-27-2024